Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) exhibit clinically significant therapeutic responses in patients with non-small cell lung cancer (NSCLC) that harbour EGFR driver mutations [1–4]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.